Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Syndax Pharmaceuticals Q2 EPS $(0.83) Beats $(1.00) Estimate, Sales $37.958M Beat $26.780M Estimate

Author: Benzinga Newsdesk | August 04, 2025 03:04pm
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.00) by 17.33 percent. This is a 3.75 percent decrease over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $37.958 million which beat the analyst consensus estimate of $26.780 million by 41.74 percent. This is a 984.51 percent increase over sales of $3.500 million the same period last year.

Posted In: SNDX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist